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Release of bronchoactive mediators from mast cells during exercise
hyperpnea is a key factor in the pathophysiology of exercise-induced
bronchoconstriction (EIB). Our aim was to investigate the effect of a
standard, single dose of an inhaled 2-adrenoceptor agonist on mast
cell activation in response to dry air hyperpnea in athletes with EIB.
Twenty-seven athletes with EIB completed a randomized, double-
blind, placebo-controlled, crossover study. Terbutaline (0.5 mg) or
placebo was inhaled 15 min prior to 8 min of eucapnic voluntary
hyperpnea (EVH) with dry air. Pre- and postbronchial challenge, urine
samples were analyzed by enzyme immunoassay for 11-prostaglan-
din F2 (11-PGF2). The maximum fall in forced expiratory volume
in 1 s of 14 (12–20)% (median and interquartile range) following
placebo was attenuated to 7 (5–9)% with the administration of
terbutaline (P  0.001). EVH caused a significant increase in 11-
PGF2 from 41 (27–57) ng/mmol creatinine at baseline to 58 (43–72)
ng/mmol creatinine at its peak post-EVH following placebo (P 
0.002). The rise in 11-PGF2 was inhibited with administration of
terbutaline: 39 (28–44) ng/mmol creatinine at baseline vs. 40 (33–58)
ng/mmol creatinine at its peak post-EVH (P  0.118). These data
provide novel in vivo evidence of mast cell stabilization following
inhalation of a standard dose of terbutaline prior to bronchial provo-
cation with EVH in athletes with EIB.
inhaled 2-agonist; exercise-induced bronchoconstriction; eucapnic
voluntary hyperpnea; prostaglandin D2
NEW & NOTEWORTHY
This study provides the first in vivo evidence for a mast cell
stabilizing effect of the short-acting inhaled 2-adrenoceptor
agonist terbutaline, when administered prophylactically at a
clinically recommended dose (0.5 mg) before bronchial prov-
ocation with dry air. Our data therefore support the proposal
that 2-adrenoceptor agonist-mediated mast cell stabilization
is a major contributor to bronchoprotection in individuals with
exercise-induced bronchoconstriction.
EXERCISE-INDUCED BRONCHOCONSTRICTION (EIB) is the transient
narrowing of airways that occurs during or shortly after stren-
uous exercise. The majority of individuals with asthma expe-
rience EIB (33), and EIB is also prevalent in children (7, 29)
and elite athletes (17). The Global Initiative for Asthma guide-
lines suggest that inhaled short-acting 2-adrenoceptor ago-
nists should be prescribed to all individuals with asthma for use
“as needed reliever” and recommends their use for the short-
term prevention of EIB (27). A recent Cochrane review of 45
studies revealed that inhaled short-acting 2-adrenoceptor ago-
nists, when taken prophylactically, reduce postexercise bron-
choconstriction by 66% in individuals with EIB (9). The
primary mechanism of this protection is believed to be func-
tional antagonism, whereby 2-adrenoceptor-induced relax-
ation of the bronchial smooth muscle opposes the contractile
effects of the various mediators of bronchoconstriction (2).
In 1975 and 1976, Anderson and colleagues (4, 5) reported
that 2-adrenoceptor agonists given by inhalation in low doses
were superior to tablets (given in much higher doses) in
preventing EIB, even though both formulations induced bron-
chodilatation. Those authors therefore proposed that the aero-
sol had an additional site of action to the smooth muscle and
prevented EIB by delivering a concentration of drug sufficient
to stabilize mast cells in the airways and inhibit the release of
“bronchoconstrictor substances.”
Evidence of mast cell activation associated with exercise and
hyperpnea of dry air is now well established by the finding of
an increase in urinary excretion of 11-prostaglandin F2
(11-PGF2), i.e., a main metabolite of prostaglandin (PG) D2,
which is produced almost exclusively from mast cells (31, 34,
35, 37, 38, 46). The proposal that inhalation of 2-adrenoceptor
agonists may prevent EIB by inhibiting release of mast cell
mediators is supported by in vitro observations of an inhibition
of IgE-dependent release of PGD2 and histamine from mast
cells with the short-acting 2-adrenoceptor agonist salbutamol
(19). In vivo, the long-acting 2-adrenoceptor agonist salmet-
erol has been shown to inhibit mast cell mediator release
following provocation with increasing doses of lysine-aspirin
in patients with aspirin-induced asthma (54). Further, a large
dose of the long-acting 2-adrenoceptor agonist formoterol has
been shown to reduce the release of 11-PGF2 following
bronchial provocation with dry powder of mannitol in patients
with asthma (15). Whether a single, standard dose of short-
acting 2-adrenoceptor agonist—the mainstay treatment for
EIB prevention—has a similar stabilizing effect on mast cells
during EIB remains to be established.
The aim of this investigation was to test the efficacy of a
single, clinically recommended dose of an inhaled short-acting
Address for reprint requests and other correspondence: P. Kippelen, College
of Health and Life Sciences, Division of Sport, Health and Exercise Sciences,
Brunel Univ. London, Uxbridge, Middlesex, UB8 3PH, U.K. (e-mail: pascale.
kippelen@brunel.ac.uk).
J Appl Physiol 120: 1011–1017, 2016.
First published February 4, 2016; doi:10.1152/japplphysiol.00700.2015.
Licensed under Creative Commons Attribution CC-BY 3.0: © the American Physiological Society. ISSN 8750-7587.http://www.jappl.org 1011
 by 10.220.32.247 on Decem
ber 6, 2017
http://jap.physiology.org/
D
ow
nloaded from
 
2-adrenoceptor agonist at inhibiting mast cell mediator re-
lease following hyperpnea with dry air. Our hypothesis was
that premedication with 0.5 mg of terbutaline would attenuate
the increase in urinary excretion of 11-PGF2 following 8
min of eucapnic voluntary hyperpnea (EVH) in athletes with
EIB.
METHODS
Subjects. Part of the current methodology has been published
elsewhere to address a separate research question (53). Twenty-seven
athletes with EIB completed the study. EIB was determined by a fall
of 10% in forced expiratory volume in 1 s (FEV1) following an
8-min EVH challenge during a screening visit. Participants were
nonsmokers, were free from any respiratory infections for 4 wk prior
to the study, and had no known chronic medical condition other than
asthma and/or EIB. Alcohol, caffeine, and exercise were withheld on
the day of testing, and medications were withheld as follows: short-
acting 2-agonist treatments for a minimum of 8 h, long-acting
2-agonist treatments for 24 h, inhaled corticosteroid treatments for
12 h, combination therapies of long-acting 2-agonist plus inhaled
corticosteroid treatments for 24 h, and nonsteroidal anti-inflammatory
medication for 7 days. Participants provided written informed consent
after the study protocol, and potential risks were explained. The study
was approved by the United Kingdom National Health Service Re-
search Ethics Committee (NHS REC reference number 10/H0716/30).
Experimental design. The study used a randomized, double-blind,
placebo-controlled, crossover experimental design with two experi-
mental visits. The experimental visits were completed within 3 wk and
separated by at least 2 days. Urine samples were collected at baseline
and at 30 and 60 min following EVH with dry air on two separate
days: one following treatment with 0.5 mg of terbutaline and one after
administration of a placebo. Urine samples were analyzed for 11-
PGF2. The primary end points were the change in the concentration
of urinary 11-PGF2 and the maximum percent fall in FEV1 follow-
ing EVH.
To standardize for fluctuations in lung function throughout the day
(42), all experimental visits commenced between 8.00 and 11.00 a.m.
Upon arrival, participants performed spirometry according to Amer-
ican Thoracic Society/European Respiratory Society guidelines (40).
A single 0.5 mg dose of terbutaline was then administered via a dry
powder inhaler (Bricanyl Turbohaler, Astra Zeneca, London, U.K.).
An empty demonstration Turbohaler was used for administration of
the placebo. The active drug (or placebo) was administered by one
deep, hard inhalation through the inhaler, followed by a 10-s breath
hold. Spirometry was repeated 10 min posttreatment.
The EVH challenge began 15 min after treatment administration.
The test consisted of 8 min of dry air hyperpnea at a target ventilation
of 85% predicted maximum voluntary ventilation (MVV; calculated
as 30  baseline FEV1) (1), with the ventilation achieved during the
first visit used as the target ventilation for the second visit. The test
was performed on a commercially available system (Eucapsys,
SMTEC, Nyon, Switzerland) that delivered a dry gas mixture con-
taining 5% CO2, 20% O2, and balance N2. Subjects recovered spon-
taneously from the EVH challenge, and spirometry was repeated in
duplicate at 2, 5, 10, 15, 20, 30, and 60 min postchallenge. The highest
of two repeatable FEV1 values was kept for analysis. The maximum
fall in FEV1 was expressed as a percentage from the posttreatment
value. The degree of bronchoprotection afforded by terbutaline was
calculated by subtracting the maximum percent fall in FEV1 on the
drug treatment day from the maximum percent fall in FEV1 on the
placebo day, and expressing it as a percentage of the placebo.
The atopic status of the participants was determined by a
standard skin prick test (12) conducted 40 min post-EVH during
the first experimental visit. The following allergens were tested:
cat hair, timothy grass, and house dust mite (ALK-Abello, Read-
ing, U.K.). Histamine and saline were used as positive and negative
controls, respectively. A test was deemed positive if the reaction
wheal was 3 mm.
Ingestion of water was standardized throughout the experimental
visits. One hour prior to the visits, subjects were asked to drink 200 ml
of water. They were given a further 400 ml upon arrival at the
laboratory, and then 200 ml every 30 min. Two baseline urine samples
were collected: the first on arrival at the laboratory, which was
discarded, and the second 30–60 min later and immediately before
administration of the drug, which was used as the baseline. Following
the EVH challenge, further urine samples were collected at 30 and 60
min. The urine samples were stored without preservatives at 80°C.
The urine samples were analyzed for 11-PGF2 using commercially
available EIA reagents (Cayman Chemical, Ann Arbor, MI) as de-
scribed elsewhere (10). Urinary data on excretion of 11-PGF2 were
normalized in relation to excretion of creatinine using the modified
Jaffe colorimetric method [as done previously (10)] and expressed as
nanograms of excreted mediator per micromole of creatinine.
Statistics. Sample size was based on a previous study in which
the mast cell stabilizing effect of sodium cromoglycate was inves-
tigated during EVH in athletes with EIB (34). With a risk alpha of
5%, a risk beta of 95%, and using the effect size from Kippelen and
colleagues (34), analysis of 16 urine samples was required
[G*Power3 software (26)].
Data were tested for normality using the Shapiro-Wilk test. Base-
line FEV1 (l), changes in FEV1 following treatment (%), ventilation
during EVH (l), level of bronchoprotection (%), and stature of the
participants were normally distributed and data are presented as
means SD. Differences between conditions for these variables were
analyzed using paired sample t-tests. All other data were nonnormally
distributed and therefore presented as median and interquartile range
(Q1–Q3). Differences between conditions for maximum change in
FEV1 (%) and urinary 11-PGF2 concentrations postchallenge were
analyzed using Wilcoxon signed-rank tests. Differences across time
were analyzed using Friedman two-way analysis of variance by ranks.
In cases of statistical significance, Wilcoxon signed-rank tests were
used to identify where differences occurred. The relationship between
the change in FEV1 (%) and the change in urinary 11-PGF2
following EVH was initially assessed via Spearman correlation tests,
in each experimental condition, separately; this was then followed by
a multiple regression analysis for within-subject repeated measures
(8). All statistical analyses were conducted using SPSS 20 (Chicago,
IL). The level of significance was set at P  0.05.
RESULTS
Participant characteristics. Age, stature, and body mass of
the participants were 23 (19–32) yr, 174  8 cm, and 71
(67–79) kg, respectively. Participants were involved in the
following sports: athletics (n  13), cycling (n  1), football
(n  4), rugby (n  1), cricket (n  1), netball (n  1), and
rowing (n  6). They were training for 8 (5–10) h/wk in
aerobic activities, and had 8 (5–12) yr experience in their sport.
Medical diagnosis, current treatment, and atopic status are
presented in Table 1.
Baseline lung function and ventilation during EVH. Baseline
FEV1 was not significantly different between conditions:
3.68  0.65 and 3.65  0.64 liters in the placebo and
terbutaline conditions, respectively (P  0.129). Terbutaline
had a small, but statistically significant (P  0.001) broncho-
dilator effect: FEV1 increased by 5  3% with administration
of terbutaline. No such bronchodilator effect was noticed after
the administration of placebo. Ventilation was slightly but
significantly (P  0.047) higher with terbutaline: 102  20 vs.
101  20 l/min (78  7 vs. 80  8% of predicted MVV).
1012 Mast Cell Inhibition by Inhaled Terbutaline • Simpson AJ et al.
J Appl Physiol • doi:10.1152/japplphysiol.00700.2015 • www.jappl.org
 by 10.220.32.247 on Decem
ber 6, 2017
http://jap.physiology.org/
D
ow
nloaded from
 
Airway response to EVH. Terbutaline significantly inhibited the
airway response to EVH. The maximum fall in FEV1 was reduced
from 14 (12–20)% in the placebo condition to 7 (5–9)% with the
administration of terbutaline (P  0.001). The degree of bron-
choprotection afforded by terbutaline was 60 30%, with a range
of 0–94%. Terbutaline afforded complete bronchoprotection
(10% fall in FEV1 post-EVH) to 22 of the 27 athletes (81%; Fig.
1). The five athletes who did not receive complete broncho-
protection did not differ from the main cohort in regard to
their previous medical diagnosis (i.e., asthma with EIB,
asthma only, EIB only, or no previous asthma/EIB diagno-
sis) or their current asthma treatment (i.e., inhaled 2-
adrenoceptor agonists, inhaled corticosteroids, or no treat-
ment).
Urinary 11-PGF2. Three participants were excluded from
statistical analysis because their 11-PGF2 concentrations were
below the level of detection. Of the 24 remaining participants, 18
had complete data sets (i.e., 11-PGF2 was detectable in all
samples), and their data were used to determine the kinetics of
urinary 11-PGF2 excretion post-EVH. An additional six partic-
ipants had acceptable baseline values and at least one acceptable
11-PGF2 value post-EVH and were therefore included in the
analysis of peak urinary 11-PGF2 release post-EVH.
Kinetics of 11-PGF2 excretion post-EVH. There was no
difference in baseline urinary 11-PGF2 values between con-
ditions (n  18; P  0.446). A significant time effect was
noted in the placebo condition (P 0.002), with an increase in
urinary 11-PGF2 from 45 (35–71) ng/mmol creatinine at
baseline to 58 (41–78) ng/mmol creatinine at 30 min postchal-
lenge (P 0.025; Fig. 2). Terbutaline completely inhibited the
rise in urinary 11-PGF2 post-EVH (P  0.446 vs. baseline).
Consequently, urinary 11-PGF2 levels were higher in the
placebo vs. the terbutaline condition at 30 min (P 0.018) and
60 min post-EVH (P  0.003; Fig. 2).
Peak of urinary 11-PGF2 post-EVH. Examination of the
baseline and peak 11-PGF2 values revealed that EVH caused
a significant increase in urinary 11-PGF2 concentration (n
24; P  0.002) that was inhibited with the inhalation of
terbutaline (P  0.118, peak vs. baseline; Fig. 3). The inhibi-
tion of 11-PGF2 excretion with terbutaline resulted in a sig-
nificantly lower peak concentration of 11-PGF2 in the ter-
butaline condition compared with the placebo condition
(P  0.001; Fig. 3). Similarly, the magnitude of the change in
urinary 11-PGF2 (prechallenge to peak postchallenge) was
significantly reduced after pretreatment with terbutaline; from 12
(5–26) ng/mmol creatinine to 3 (4 to 9) ng/mmol creatinine in
the placebo and terbutaline condition, respectively (P  0.033).
Spearman rank correlation coefficient revealed a weak, pos-
itive relationship (r2  0.251; P  0.013) between the fall in
FEV1 and the change in urinary 11-PGF2 (baseline to peak)
post-EVH in the placebo condition. This relationship was
absent with the administration of terbutaline (P  0.505).
Furthermore, multiple regression analysis revealed no signifi-
cant relationship between the magnitude of change in urinary
11-PGF2 and the fall in FEV1 post-EVH (P  0.117).
DISCUSSION
The aim of this study was to determine whether a standard,
single dose of inhaled short-acting 2-adrenoceptor agonist
Table 1. Participant characteristics
ID Gender Atopic Status Baseline FEV1, % Predicted Previous Diagnosis Treatment Prescribed ICS Dose, g/day
1 M 	 95 Asthma	EIB Combination, SABA 1,600
2 M 	 92 Asthma SABA, ICS 200
3 M 	 99 Asthma	EIB Combination 400
4 F 	 108 EIB SABA, ICS 200
5 M 	 97   
6 F 	 92 Asthma SABA, ICS 200
7 M 	 93 Asthma	EIB SABA 
8 F 	 93 Asthma Combination 400
9 M 	 99 Asthma SABA, ICS 600
10 M  99   
11 M 	 85 Asthma  
12 F 	 103 Asthma  
13 M 	 109 EIB SABA 
14 F  99 Asthma	EIB Combination 400
15 F  109   
16 M 	 94 Asthma SABA 
17 F  96 Asthma SABA 
18 M 	 94 Asthma SABA 
19 M 	 111 Asthma SABA, ICS 200
20 F 	 102 EIB SABA, ICS 200
21 F 	 86 Asthma SABA 
22 F  88 EIB  
23 F 	 82 Asthma	EIB SABA 
24 M 	 91 Asthma SABA 
25* M 	 102 Asthma SABA 
26* M  85 Asthma Combination 200
27* M 	 109 Asthma	EIB ICS 100
Atopic status: 	, positive skin prick response to house dust mite, timothy grass, and/or cat hair; FEV1 % predicted, baseline forced expiratory volume in 1
s expressed relative to the predicted value (50); EIB, exercise-induced bronchoconstriction; SABA, short-acting 2-agonist; LABA, long-acting 2-agonist; ICS,
inhaled corticosteroids; combination, combination therapy of LABA and ICS; *participants who had urinary 11-PGF2 concentrations below the level of
detection.
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inhibits mast cell mediator release in a model of EIB. Our
results demonstrate that 0.5 mg of terbutaline is able to inhibit
the rise in urinary 11-PGF2 excretion following hyperpnea
of dry air in athletes with EIB. These results provide the first in
vivo evidence of an inhibition of mast cell activation by a low,
clinically recommended dose of inhaled short-acting 2-adre-
noceptor agonist in response to indirect bronchial provocation.
This study supports previous findings of mast cell activation
following hyperpnea of dry air in athletes (34, 35). In vivo
evidence using 11-PGF2 to assess the mast cell stabilizing
effect of inhaled 2-adrenoceptor agonists in a model of EIB
(i.e., bronchial provocation with dry powder mannitol) is
limited to the use of a large dose of the long-acting 2-
adrenoceptor agonist formoterol (15). Long-acting 2-adreno-
ceptor agonists are, however, not recommended as mono-
therapy for the treatment of asthma (27) or EIB (48). We
therefore add novel, clinically relevant data, demonstrating that
mast cell stabilization can occur following inhalation of a
standard, single dose of the short-acting 2-adrenoceptor ago-
nist terbutaline.
Mast cell activation in this study was assessed by a change
in the urinary concentration of 11-PGF2. PGD2, the parent
molecule of 11-PGF2, is a major cyclooxygenase metabolite
of arachidonic acid. In humans, PGD2 is produced almost
exclusively from mast cells (47), rendering the urinary metab-
olite 11-PGF2 a reliable and convenient marker of mast cell
activation (47). A rise in urinary excretion of 11-PGF2 has
repeatedly been observed following induced bronchoconstric-
tion in humans, irrespective of the trigger used: allergen (the
gold-standard of mast cell dependent bronchoconstriction)
(45), exercise (31, 39, 43, 46), EVH (34, 35), or mannitol (14,
15, 37). Further, in vitro work suggests that human mast cells
are activated not only by antigen stimulation but also through
osmotic stress (28). In the present study, the average ventila-
tion of 
100 l/min would have caused water loss from the
smaller airways and local hyperosmolarity of the airway sur-
face liquid (22). This is relevant because mast cells are more
densely located in the peripheral airways (6, 18). Furthermore,
an increase in mast cell density has been noted in individuals
with asthma and EIB (36), as well as in competitive swimmers
(11). An increase in mast cell density in the peripheral airways,
combined with the capability of hyperpnea of dry air to create
a hyperosmotic environment, may explain the rise in 11-
PGF2 in the placebo condition in the present study.
Importantly, the deposition of terbutaline from a dry powder
inhaler also extends to the small airways (44). This may have
facilitated the binding of terbutaline with the 2-adrenoceptors
on the mast cells infiltrated in the peripheral airways of our
study participants. In vitro, mast cells treated with the nonse-
lective -adrenergic agonist isoprenaline displayed increased
levels of cAMP (49). Furthermore, this increase in cAMP
correlated with a reduction in the release of the mast cell
mediators PGD2, histamine, and leukotriene C4 (49). In vivo,
inhaled terbutaline has also been shown to increase plasma
cAMP (16). Because pharmacological agents that induce and
sustain elevations of intracellular cAMP are well known to
supress mast cell secretions (56), it is likely that the inhibitory
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Fig. 1. Maximum fall in forced expiratory volume in 1 s (FEV1) following 8
min of hyperpnea of dry air in athletes with exercise-induced bronchoconstric-
tion pretreated with 0.5 mg terbutaline (closed symbols) or placebo (open
symbols). Individual data are shown; box plots represent group median and
interquartile range, with whiskers representing the 5th and 95th percentiles.
Values under the broken line (10% fall in FEV1) represent complete broncho-
protection (n  22, 81%).
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Fig. 2. Median  interquartile range (Q1–Q3) urinary concentration of 11-
prostaglandin F2 (11-PGF2) at baseline and 30 and 60 min post-eucapnic
voluntary hyperpnea of dry air following pretreatment with 0.5 mg terbutaline
(closed circles) or placebo (open circles) in 18 athletes with exercise-induced
bronchoconstriction.
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effect of mast cell mediator release provided by terbutaline was
partly mediated by 2-adrenoceptor-induced increase of intra-
cellular cAMP.
Our data support the early proposal by Anderson and col-
leagues (4, 5) that inhaled 2-adrenoceptor agonist may atten-
uate EIB at least partly by inhibiting mast cell activation. We
previously showed that inhaled sodium cromoglycate attenu-
ates bronchoconstriction and urinary 11-PGF2 excretion
following EVH (34). Because sodium cromoglycate has no
known bronchorelaxant effect on airway smooth muscle (20,
55), we concluded that sodium cromoglycate attenuates hyper-
pnea-induced bronchoconstriction via mast cell stabilization
(34). Similarly here, we propose that the prophylactic effect of
terbutaline was partly mediated by inhibition of mast cell
mediator release. This new observation in EVH is in keep-
ing with previous data for allergen-induced bronchocon-
striction, where albuterol offered significant bronchoprotec-
tion in association with the inhibition of mast cell mediator
release (32). However, we cannot dismiss other possible
modes of action of 2-adrenoceptor agonists within the
airways. This would be in keeping with the absence of a
relationship between bronchoconstriction (i.e., maximum
fall in FEV1 post-EVH) and urinary 11-PGF2 excretion
(as observed in our multiple regression analysis), which may
be explained by interindividual variation in the contribution
of alternative modes of action of terbutaline.
Terbutaline has previously been shown to reduce airway
plasma exudation (25). Since vascular engorgement and edema
in response to hyperpnea are thought to exaggerate airway
obstruction in EIB (3), the antiexudative action of 2-adreno-
ceptor agonists may have contributed to bronchoprotection in
our study. Furthermore, there is a possibility that the 2-
adrenoceptor agonist may have limited excessive and viscous
mucosal accumulation by increasing cilia beat frequency (23)
and improving clearance of alveolar (51) and/or mucociliary
fluids (21, 41). Finally, the 2-adrenoceptor agonist may have
preserved/improved airway caliber due to its well-known effect
on airway smooth muscle tone. However, it has previously
been reported that large doses of orally administered 2-
adrenoceptor agonists fail to prevent EIB while providing
significant bronchodilatation (4, 5). Given these observa-
tions and our results showing a marked reduction in PGD2
release, we consider that mast cell stabilization was an
important contributor to the bronchoprotection in our exper-
imental set-up.
Mast cell stabilizing treatments are deemed beneficial for the
treatment of asthma/airway hyperresponsiveness (AHR) (13).
Further, athletes have an increased prevalence of EIB (17), and
mast cell activation has been observed in this population during
dry air challenge independently to the occurrence of EIB (34,
35). Our findings are therefore of clinical relevance to individ-
uals with asthma/AHR and to athletes. Given that PGD2 may
perpetuate inflammation via initiation of the migration of
eosinophils to the airways (24), the prevention of mast cell
mediator release with 2-adrenoceptor agonists may interrupt
the chronic inflammatory cycle and improve the management
of asthma and/or EIB. Importantly, however, a side effect of
regular 2-adrenoceptor agonist usage may include the devel-
opment of tolerance to the medication (30). Therefore, changes
to the current guidelines for the management of EIB are not
recommended at this time; the use of controller agents, such as
inhaled corticosteroids, should be promoted when inhaled
2-adrenoceptor agonists have to be used frequently (48). It
remains to be determined whether tolerance to 2-adrenoceptor
agonists is associated in vivo with tolerance to their effects at
the level of release of mast cell mediators (52).
To conclude, we have shown that the prophylactic adminis-
tration of 0.5 mg of inhaled terbutaline not only offers a
significant degree of bronchoprotection to athletes with EIB,
but is also able to inhibit the release of the mast cell mediator
PGD2 following hyperpnea of dry air. These findings are in
keeping with the proposal that the superior efficacy of aerosol
formulation of 2-adrenoceptor agonist compared with tablets
for preventing EIB is the inhibition of release of mast cell
mediators (4, 5).
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Fig. 3. Urinary concentrations of 11-PGF2 at base-
line and after eucapnic voluntary hyperpnea (EVH) of
dry air (peak value) following pretreatment with 0.5
mg terbutaline (closed circles) or placebo (open cir-
cles) in 24 athletes with exercise-induced bronchoc-
onstriction. Individual data are shown; box plots rep-
resent group median and interquartile range, with
whiskers representing the 5th and 95th percentiles.
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